Traws Pharma, Inc. (TRAW) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
TRAW Revenue Growth
TRAW Revenue Analysis (2013–2024)
As of May 8, 2026, Traws Pharma, Inc. (TRAW) generated trailing twelve-month (TTM) revenue of $3.0 million, reflecting explosive growth of +4780.4% year-over-year. The most recent quarter (Q2 2025) recorded $2.7 million in revenue, up 4694.7% sequentially.
Looking at the longer-term picture, TRAW's 5-year compound annual growth rate (CAGR) stands at -36.5%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $11.5 million in 2015.
When compared to Healthcare sector peers including VRTX (+10.4% YoY), GILD (+3.5% YoY), and INVA (+13.6% YoY), TRAW has outperformed the peer group in terms of revenue growth. Compare TRAW vs VRTX →
TRAW Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| TRAWCurrent | $3M | +4780.4% | -36.5% | -21835.4% | |
 VRTX | $12.1B | +10.4% | +14.2% | 39.4% | |
 GILD | $29.4B | +3.5% | +3.6% | 40.1% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% |
TRAW Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $226K | +0.0% | $214K | 94.7% | $-49,348,000 | -21835.4% |
| 2023 | $226K | +0.0% | $226K | 100.0% | $-20,298,000 | -8981.4% |
| 2022 | $226K | +0.0% | $226K | 100.0% | $-19,627,000 | -8684.5% |
| 2021 | $226K | -2.2% | $226K | 100.0% | $-16,496,000 | -7299.1% |
| 2020 | $231K | -89.4% | $231K | 100.0% | $-24,993,000 | -10819.5% |
| 2019 | $2.2M | +77.8% | $2.2M | 100.0% | $-21,699,000 | -994.0% |
| 2018 | $1.2M | +56.0% | $0 | - | $-23,282,000 | -1895.9% |
| 2017 | $787K | -85.8% | $0 | - | $-25,737,000 | -3270.3% |
| 2016 | $5.5M | -51.6% | $0 | - | $-23,703,000 | -427.4% |
| 2015 | $11.5M | +1332.0% | $0 | - | $-23,972,000 | -209.3% |
See TRAW's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TRAW Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TRAW vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTRAW — Frequently Asked Questions
Quick answers to the most common questions about buying TRAW stock.
Is TRAW's revenue growth accelerating or slowing?
TRAW revenue is accelerating at +4780.4% year-over-year, exceeding the 5-year CAGR of -36.5%. TTM revenue reached $3M. Growth momentum has increased versus prior periods.
What is TRAW's long-term revenue growth rate?
Traws Pharma, Inc.'s 5-year revenue CAGR of -36.5% reflects the sustained expansion pattern. Current YoY growth of +4780.4% is above this long-term average.
How is TRAW's revenue distributed by segment?
TRAW reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.